ADVENTRX Pharmaceuticals Company Description
ADVENTRX Pharmaceuticals hopes to balance adventure with profits with its investigational drug treatments for cancer and infectious diseases. Its lead cancer candidates are improved formulations of existing treatments that aim to reduce the toxic side effects of most chemotherapies. The company is also developing CoFactor, which may enhance the effectiveness of popular chemotherapy 5-FU. Though its cancer programs are its main focus, ADVENTRX also owns the rights to a number of potential infectious disease compounds, including treatments for bacterial infections, HIV, and influenza.
View the Comprehensive Company Description for ADVENTRX Pharmaceuticals
The Company Description provides a historical perspective of ADVENTRX Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of ADVENTRX Pharmaceuticals's evolution in the marketplace.
